Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness

July 26, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search